KRAS Frontier– category –
-
Where Will KRAS Drug Discovery Be Beyond 2027? Player Map and 5 Reshuffling Scenarios | KRAS Frontier Vol.3 (Final)
Competitive map of Revolution, Amgen, BMS, Roche, Lilly, BioNTech, Moderna; SHP2/SOS1 inhibitors, mRNA vaccines, diagnostic linkage, 2027-2030 outlook. -
Redrawing the KRAS Map: G12D, Pan-KRAS, and Degraders Open 4 New Frontiers | KRAS Frontier Vol.2
Revolution Medicines daraxonrasib (pan-RAS) achieved Phase 3 PDAC OS 13.2 vs 6.7 months; zoldonrasib (G12D) earned FDA Breakthrough in NSCLC. -
Where Are KRAS G12C Inhibitors Heading? Sotorasib, Adagrasib, and the 5 Axes of Resistance in 2026 | KRAS Frontier Vol.1
Sotorasib / adagrasib 2026 clinical status, resistance mechanisms (switch II mutations, EGFR reactivation), KRYSTAL-7 ICI combinations, CRC anti-EGFR approvals.
1